StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Saturday. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald restated an overweight rating and set a $2.50 price objective on shares of VolitionRx in a report on Wednesday, March 27th.

VolitionRx Price Performance

Shares of VNRX traded up $0.01 during midday trading on Friday, hitting $0.89. The stock had a trading volume of 108,909 shares, compared to its average volume of 320,236. VolitionRx has a 1 year low of $0.55 and a 1 year high of $2.09. The stock’s 50 day moving average is $0.83 and its 200 day moving average is $0.85. The firm has a market cap of $73.12 million, a PE ratio of -1.75 and a beta of 1.26.

VolitionRx (NYSE:VNRX) last posted its quarterly earnings data on Monday, March 25th. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million. As a group, equities research analysts expect that VolitionRx will post -0.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx as of its most recent filing with the Securities & Exchange Commission. 8.09% of the stock is owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.